{
    "info": {
        "nct_id": "NCT03310541",
        "official_title": "A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3",
        "inclusion_criteria": "* Pathologically confirmed recurrent or metastatic advanced solid tumor, for which there is no curative-intent treatment option and confirmation of the presence of AKT1, AKT2, or AKT3 mutations detected by the MSK-IMPACT assay platform or other CLIA-approved test\n* ER+ breast cancer patients must have received and progressed on Fulvestrant and be post-menopausal\n* Prostate cancer patients must have received and progressed on enzalutamide\n* Age ≥ 18 years\n* ECOG performance status ≤ 2 with no deterioration over the previous 2 weeks\n* Life expectancy of ≥ 12 weeks\n* Measurable disease as defined by the tumor specific relevant response criteria for the breast and other solid tumor cohorts (measurable disease is not required for enrollment in the prostate cancer cohort):\n\n  * RECIST version 1.1 criteria\n  * Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.\n  * RANO criteria\n* Females should be using adequate contraceptive measures (see Section 0), should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as:\n  * Aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments\n  * Estradiol, FSH and LH levels in post-menopausal range while receiving LHRH analogues for medical castration in patients with breast cancer.\n  * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\n* Male patients should be willing to use barrier contraception (i.e. condoms)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* ER+ breast cancer patients harboring the AKT1 E17K mutation (patient population tested in MSK IRB# 14-214, study D3610C00001 part E, ClinicalTrials.gov NCT01226316).\n* Diabetes mellitus type 1\n* Fasting plasma glucose [fasting is defined as no calorific intake for at least 8 hours]:\n\n  * ≥ 126 mg/dL for those patients without a pre-existing diagnosis of Type 2 diabetes mellitus\n  * ≥ 167mg/dL for those patients with a pre-existing diagnosis of Type 2 diabetes mellitus\n* Glycosylated haemoglobin (HbA1C) ≥8.0%\n* Requirement for insulin for routine diabetic management and control\n* Requirement for >2 oral hypoglycaemic medications for routine diabetic management and control\n* Treatment with any of the following:\n\n  * Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment\n  * Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks or 5 half lives, whichever is longer, of the first dose of study treatment, except fulvestrant, enzalutamide or hormonal therapy with LHRH analogues for medical castration in patients with breast or prostate cancer, which are permitted\n  * Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John\"s Wort).\n  * Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment\n  * Radiotherapy with a wide field of radiation within 4 weeks of the first dose of study treatment\n  * Prior ATP-competitive AKT inhibitors\n* With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment\n* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment\n* As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus. Screening for chronic conditions is not required.\n* Any of the following cardiac criteria:\n\n  * Resting corrected QT interval (QTc) > 480 msec obtained from electrocardiogram (ECG)\n  * Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) eg, complete left bundle branch block, third degree heart block\n  * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval\n  * Experience of any of the following procedures or conditions in the preceding 6 months and judged to be clinically significant by Principle Investigator: : coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade ≥2\n  * Uncontrolled hypotension - Systolic blood pressure (BP) <90mmHg and/or diastolic BP <50mmHg\n  * Left ventricular ejection fraction (LVEF) below lower limit of normal for site.\n* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n  * Absolute neutrophil count < 1 x 10^9/L\n  * Platelet count < 100 x 10^9/L\n  * Haemoglobin < 9.0 g/dL\n  * ALT > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases, or >5 times ULN in presence of liver metastases\n  * AST > 2.5 times ULN if no demonstrable liver metastases, or >5 times ULN in presence of liver metastases.\n  * Total bilirubin > 1.5 times ULN (patients with confirmed Gilbert\"s syndrome may be included in the study)\n  * Creatinine >1.5 times ULN concurrent with creatinine clearance < 50 ml/min; confirmation of creatinine clearance is only required when creatinine is > 1.5 times ULN\n  * Proteinuria 3+ on dipstick analysis or >500 mg/24 hours\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5363\n* History of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide or drugs with a similar chemical structure or class to these agents.\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Post-menopausal defined as:",
            "criterions": [
                {
                    "exact_snippets": "Post-menopausal defined as:",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of ≥ 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of ≥ 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease as defined by the tumor specific relevant response criteria for the breast and other solid tumor cohorts (measurable disease is not required for enrollment in the prostate cancer cohort):",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by the tumor specific relevant response criteria for the breast and other solid tumor cohorts",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "as defined by the tumor specific relevant response criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease is not required for enrollment in the prostate cancer cohort",
                    "criterion": "measurable disease (prostate cancer cohort)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.",
            "criterions": [
                {
                    "exact_snippets": "Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy",
                    "criterion": "irreversible surgical sterilisation",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "hysterectomy",
                                "bilateral oophorectomy",
                                "bilateral salpingectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "but not tubal ligation",
                    "criterion": "tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.",
            "criterions": [
                {
                    "exact_snippets": "Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria",
                    "criterion": "PCWG3 criteria",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females should be using adequate contraceptive measures (see Section 0), should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:",
            "criterions": [
                {
                    "exact_snippets": "Females should be using adequate contraceptive measures",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "adequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "should not be breast feeding",
                    "criterion": "breast feeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test prior to start of dosing if of child-bearing potential",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to start of dosing"
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "if of child-bearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening",
                    "criterion": "child-bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "non-child-bearing"
                        },
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients should be willing to use barrier contraception (i.e. condoms)",
            "criterions": [
                {
                    "exact_snippets": "Male patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "should be willing to use barrier contraception (i.e. condoms)",
                    "criterion": "willingness to use barrier contraception",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": "barrier (condoms)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate cancer patients must have received and progressed on enzalutamide",
            "criterions": [
                {
                    "exact_snippets": "Prostate cancer patients",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have received ... enzalutamide",
                    "criterion": "enzalutamide treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressed on enzalutamide",
                    "criterion": "disease progression on enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estradiol, FSH and LH levels in post-menopausal range while receiving LHRH analogues for medical castration in patients with breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "Estradiol ... in post-menopausal range while receiving LHRH analogues for medical castration",
                    "criterion": "estradiol level",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "post-menopausal range"
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "while receiving LHRH analogues for medical castration"
                        }
                    ]
                },
                {
                    "exact_snippets": "FSH ... in post-menopausal range while receiving LHRH analogues for medical castration",
                    "criterion": "FSH level",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "post-menopausal range"
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "while receiving LHRH analogues for medical castration"
                        }
                    ]
                },
                {
                    "exact_snippets": "LH ... in post-menopausal range while receiving LHRH analogues for medical castration",
                    "criterion": "LH level",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "post-menopausal range"
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "while receiving LHRH analogues for medical castration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments",
            "criterions": [
                {
                    "exact_snippets": "Aged more than 50 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrhoeic for at least 12 months",
                    "criterion": "amenorrhoea",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "following cessation of all exogenous hormonal treatments",
                    "criterion": "exogenous hormonal treatment",
                    "requirements": [
                        {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ER+ breast cancer patients must have received and progressed on Fulvestrant and be post-menopausal",
            "criterions": [
                {
                    "exact_snippets": "ER+ breast cancer patients",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have received and progressed on Fulvestrant",
                    "criterion": "Fulvestrant treatment history",
                    "requirements": [
                        {
                            "requirement_type": "received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progressed_on",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be post-menopausal",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 2 with no deterioration over the previous 2 weeks",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no deterioration over the previous 2 weeks",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "deterioration over the previous 2 weeks",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* RANO criteria",
            "criterions": [
                {
                    "exact_snippets": "RANO criteria",
                    "criterion": "RANO criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* RECIST version 1.1 criteria",
            "criterions": [
                {
                    "exact_snippets": "RECIST version 1.1 criteria",
                    "criterion": "RECIST version 1.1 criteria",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed recurrent or metastatic advanced solid tumor, for which there is no curative-intent treatment option and confirmation of the presence of AKT1, AKT2, or AKT3 mutations detected by the MSK-IMPACT assay platform or other CLIA-approved test",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed recurrent or metastatic advanced solid tumor",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathologically confirmed"
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "recurrent",
                                "metastatic",
                                "advanced"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which there is no curative-intent treatment option",
                    "criterion": "curative-intent treatment option",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmation of the presence of AKT1, AKT2, or AKT3 mutations detected by the MSK-IMPACT assay platform or other CLIA-approved test",
                    "criterion": "AKT1, AKT2, or AKT3 mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": [
                                "MSK-IMPACT assay platform",
                                "other CLIA-approved test"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior ATP-competitive AKT inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior ATP-competitive AKT inhibitors",
                    "criterion": "prior use of ATP-competitive AKT inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 167mg/dL for those patients with a pre-existing diagnosis of Type 2 diabetes mellitus",
            "criterions": [
                {
                    "exact_snippets": "≥ 167mg/dL for those patients with a pre-existing diagnosis of Type 2 diabetes mellitus",
                    "criterion": "blood glucose level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 167,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "pre-existing diagnosis of Type 2 diabetes mellitus"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Experience of any of the following procedures or conditions in the preceding 6 months and judged to be clinically significant by Principle Investigator: : coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade ≥2",
            "criterions": [
                {
                    "exact_snippets": "coronary artery bypass graft ... in the preceding 6 months ... judged to be clinically significant by Principle Investigator",
                    "criterion": "coronary artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "history in preceding 6 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (per PI)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "angioplasty ... in the preceding 6 months ... judged to be clinically significant by Principle Investigator",
                    "criterion": "angioplasty",
                    "requirements": [
                        {
                            "requirement_type": "history in preceding 6 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (per PI)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vascular stent ... in the preceding 6 months ... judged to be clinically significant by Principle Investigator",
                    "criterion": "vascular stent",
                    "requirements": [
                        {
                            "requirement_type": "history in preceding 6 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (per PI)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... in the preceding 6 months ... judged to be clinically significant by Principle Investigator",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history in preceding 6 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (per PI)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "angina pectoris ... in the preceding 6 months ... judged to be clinically significant by Principle Investigator",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "history in preceding 6 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (per PI)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure New York Heart Association (NYHA) Grade ≥2 ... in the preceding 6 months ... judged to be clinically significant by Principle Investigator",
                    "criterion": "congestive heart failure (NYHA Grade)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA Grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "history in preceding 6 months",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (per PI)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Resting corrected QT interval (QTc) > 480 msec obtained from electrocardiogram (ECG)",
            "criterions": [
                {
                    "exact_snippets": "Resting corrected QT interval (QTc) > 480 msec ... obtained from electrocardiogram (ECG)",
                    "criterion": "resting corrected QT interval (QTc)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": "electrocardiogram (ECG)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diabetes mellitus type 1",
            "criterions": [
                {
                    "exact_snippets": "Diabetes mellitus type 1",
                    "criterion": "diabetes mellitus type 1",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Glycosylated haemoglobin (HbA1C) ≥8.0%",
            "criterions": [
                {
                    "exact_snippets": "Glycosylated haemoglobin (HbA1C) ≥8.0%",
                    "criterion": "glycosylated haemoglobin (HbA1C)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requirement for insulin for routine diabetic management and control",
            "criterions": [
                {
                    "exact_snippets": "Requirement for insulin for routine diabetic management and control",
                    "criterion": "insulin requirement for diabetes management",
                    "requirements": [
                        {
                            "requirement_type": "requirement for insulin",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count < 100 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count < 100 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 126 mg/dL for those patients without a pre-existing diagnosis of Type 2 diabetes mellitus",
            "criterions": [
                {
                    "exact_snippets": "≥ 126 mg/dL for those patients without a pre-existing diagnosis of Type 2 diabetes mellitus",
                    "criterion": "blood glucose level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 126,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "pre-existing diagnosis of Type 2 diabetes mellitus",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy with a wide field of radiation within 4 weeks of the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy with a wide field of radiation within 4 weeks of the first dose of study treatment",
                    "criterion": "radiotherapy with a wide field of radiation",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to first dose of study treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypotension - Systolic blood pressure (BP) <90mmHg and/or diastolic BP <50mmHg",
            "criterions": [
                {
                    "exact_snippets": "Systolic blood pressure (BP) <90mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic BP <50mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval",
            "criterions": [
                {
                    "exact_snippets": "Any factors that increase the risk of QTc prolongation",
                    "criterion": "risk factors for QTc prolongation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "risk of arrhythmic events",
                    "criterion": "risk factors for arrhythmic events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "heart failure",
                    "criterion": "heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypokalaemia",
                    "criterion": "hypokalaemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congenital long QT syndrome",
                    "criterion": "congenital long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of long QT syndrome",
                    "criterion": "family history of long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of ... unexplained sudden death under 40 years of age",
                    "criterion": "family history of unexplained sudden death under 40 years of age",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any concomitant medication known to prolong the QT interval",
                    "criterion": "concomitant medication known to prolong the QT interval",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST > 2.5 times ULN if no demonstrable liver metastases, or >5 times ULN in presence of liver metastases.",
            "criterions": [
                {
                    "exact_snippets": "AST > 2.5 times ULN if no demonstrable liver metastases",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "liver metastases",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": ">5 times ULN in presence of liver metastases",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "liver metastases",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requirement for >2 oral hypoglycaemic medications for routine diabetic management and control",
            "criterions": [
                {
                    "exact_snippets": "Requirement for >2 oral hypoglycaemic medications for routine diabetic management and control",
                    "criterion": "oral hypoglycaemic medications",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "medications"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "routine diabetic management and control"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment",
                    "criterion": "spinal cord compression or brain metastases (if present)",
                    "requirements": [
                        {
                            "requirement_type": "symptoms",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": "treated"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        },
                        {
                            "requirement_type": "steroid_requirement_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) below lower limit of normal for site.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) below lower limit of normal for site",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "lower limit of normal for site"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following cardiac criteria:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following cardiac criteria",
                    "criterion": "cardiac criteria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count < 1 x 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count < 1 x 10^9/L",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Haemoglobin < 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Haemoglobin < 9.0 g/dL",
                    "criterion": "haemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Proteinuria 3+ on dipstick analysis or >500 mg/24 hours",
            "criterions": [
                {
                    "exact_snippets": "Proteinuria 3+ on dipstick analysis",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "dipstick analysis result",
                            "expected_value": "3+"
                        }
                    ]
                },
                {
                    "exact_snippets": "Proteinuria ... >500 mg/24 hours",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "mg/24 hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5363",
            "criterions": [
                {
                    "exact_snippets": "Refractory nausea and vomiting",
                    "criterion": "nausea and vomiting",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic gastrointestinal diseases",
                    "criterion": "gastrointestinal diseases",
                    "requirements": [
                        {
                            "requirement_type": "chronic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to swallow the formulated product",
                    "criterion": "ability to swallow formulated product",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "previous significant bowel resection that would preclude adequate absorption of AZD5363",
                    "criterion": "previous significant bowel resection",
                    "requirements": [
                        {
                            "requirement_type": "effect on AZD5363 absorption",
                            "expected_value": "would preclude adequate absorption"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) eg, complete left bundle branch block, third degree heart block",
            "criterions": [
                {
                    "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG)",
                    "criterion": "resting electrocardiogram (ECG)",
                    "requirements": [
                        {
                            "requirement_type": "abnormalities in rhythm",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abnormalities in conduction",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abnormalities in morphology",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "complete left bundle branch block",
                    "criterion": "left bundle branch block",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": "complete"
                        }
                    ]
                },
                {
                    "exact_snippets": "third degree heart block",
                    "criterion": "heart block",
                    "requirements": [
                        {
                            "requirement_type": "degree",
                            "expected_value": "third"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin > 1.5 times ULN (patients with confirmed Gilbert\"s syndrome may be included in the study)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin > 1.5 times ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with confirmed Gilbert\"s syndrome may be included in the study",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide or drugs with a similar chemical structure or class to these agents.",
            "criterions": [
                {
                    "exact_snippets": "History of hypersensitivity to active or inactive excipients of AZD5363, fulvestrant and enzalutamide",
                    "criterion": "hypersensitivity to excipients of AZD5363, fulvestrant, and enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of hypersensitivity to ... drugs with a similar chemical structure or class to these agents",
                    "criterion": "hypersensitivity to drugs with similar chemical structure or class to AZD5363, fulvestrant, or enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fasting plasma glucose [fasting is defined as no calorific intake for at least 8 hours]:",
            "criterions": [
                {
                    "exact_snippets": "Fasting plasma glucose [fasting is defined as no calorific intake for at least 8 hours]",
                    "criterion": "fasting plasma glucose",
                    "requirements": [
                        {
                            "requirement_type": "fasting state",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any of the following:",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "any of the following"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus. Screening for chronic conditions is not required.",
            "criterions": [
                {
                    "exact_snippets": "any evidence of severe or uncontrolled systemic diseases",
                    "criterion": "systemic diseases",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "active bleeding diatheses",
                    "criterion": "bleeding diatheses",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection including hepatitis B, hepatitis C and human immunodeficiency virus",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "hepatitis B",
                                "hepatitis C",
                                "human immunodeficiency virus"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment",
                    "criterion": "use of investigational agents or study drugs from a previous clinical study",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ER+ breast cancer patients harboring the AKT1 E17K mutation (patient population tested in MSK IRB# 14-214, study D3610C00001 part E, ClinicalTrials.gov NCT01226316).",
            "criterions": [
                {
                    "exact_snippets": "ER+ breast cancer patients",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "harboring the AKT1 E17K mutation",
                    "criterion": "AKT1 E17K mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALT > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases, or >5 times ULN in presence of liver metastases",
            "criterions": [
                {
                    "exact_snippets": "ALT > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "liver metastases",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": ">5 times ULN in presence of liver metastases",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "times ULN"
                            }
                        },
                        {
                            "requirement_type": "liver metastases",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",
            "criterions": [
                {
                    "exact_snippets": "the patient is unlikely to comply with study procedures, restrictions and requirements",
                    "criterion": "compliance with study procedures, restrictions and requirements",
                    "requirements": [
                        {
                            "requirement_type": "likelihood of compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Judgment by the investigator that the patient should not participate in the study",
                    "criterion": "investigator judgment regarding participation",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "should not participate if unlikely to comply"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment",
                    "criterion": "toxicities from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "resolved or CTCAE grade 1 or lower"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "With the exception of alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine >1.5 times ULN concurrent with creatinine clearance < 50 ml/min; confirmation of creatinine clearance is only required when creatinine is > 1.5 times ULN",
            "criterions": [
                {
                    "exact_snippets": "Creatinine >1.5 times ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance < 50 ml/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks or 5 half lives, whichever is longer, of the first dose of study treatment, except fulvestrant, enzalutamide or hormonal therapy with LHRH analogues for medical castration in patients with breast or prostate cancer, which are permitted",
            "criterions": [
                {
                    "exact_snippets": "Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks or 5 half lives, whichever is longer, of the first dose of study treatment",
                    "criterion": "prior chemotherapy, immunotherapy, or anticancer agents",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except fulvestrant, enzalutamide or hormonal therapy with LHRH analogues for medical castration in patients with breast or prostate cancer, which are permitted",
                    "criterion": "use of fulvestrant, enzalutamide, or hormonal therapy with LHRH analogues for medical castration in patients with breast or prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "permitted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:",
            "criterions": [
                {
                    "exact_snippets": "Inadequate bone marrow reserve",
                    "criterion": "bone marrow reserve",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "inadequate ... organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John\"s Wort).",
            "criterions": [
                {
                    "exact_snippets": "Potent inhibitors or inducers or substrates of CYP3A4 ... within 2 weeks before the first dose of study treatment",
                    "criterion": "use of potent inhibitors, inducers, or substrates of CYP3A4",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "substrates of CYP2D6 within 2 weeks before the first dose of study treatment",
                    "criterion": "use of substrates of CYP2D6",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "St John\"s Wort ... within 3 weeks before the first dose of study treatment",
                    "criterion": "use of St John's Wort",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}